摘要
血浆脂蛋白相关磷脂酶A2(LP-PLA2)由成熟的巨噬细胞和淋巴细胞合成和分泌,又称血小板活化因子乙酰水解酶(PAF-AH),在血浆中主要与低密度脂蛋白结合。近年来,越来越多研究表明在动脉粥样硬化的发病机制及预防性治疗上,LP-PLA2是动脉粥样硬化中的一个新的炎性反应标志物,可能成为冠心病治疗的新靶点。
Lipoplrotein-associated phospholipase A2 （Lp-PLA2）, also named platelet-activating factor, synthesized and secreted by ripe macrophage and lymphocyte, which are transported in human plasma mainly bound together with low-density lipoprotein. Research in rerent years indicates the necessity of studying Lp-PLA2 as a new inflammatory marker factor in pathogenesis and prophylactic treatment of atheroselerosis, and Lp-PLA2 may become an new therapeutic target of coronary heart disease.
出处
《中国实用医药》
2009年第5期226-230,共5页
China Practical Medicine
关键词
脂蛋白相关性磷脂酶A2
动脉粥样硬化
冠心病
Lipoplotein-assoeiated phospholipaseA2
Atheroselerosis
Coronary Heart Diseae
